Search

Your search keyword '"Hadoux, J."' showing total 305 results
Start Over Author "Hadoux, J."
305 results on '"Hadoux, J."'

3. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study

Author

Bayle, A., Belcaid, L., Aldea, M., Vasseur, D., Peyraud, F., Nicotra, C., Geraud, A., Sakkal, M., Seknazi, L., Cerbone, L., Blanc-Durand, F., Hadoux, J., Mosele, F., Tagliamento, M., Bernard-Tessier, A., Verret, B., Smolenschi, C., Clodion, R., Auger, N., Romano, P.M., Gazzah, A., Camus, M.N., Micol, J., Caron, O., Hollebecque, A., Loriot, Y., Besse, B., Lacroix, L., Rouleau, E., Ponce, S., Soria, J.C., Barlesi, F., Andre, F., and Italiano, A.

Published
2023
Full Text
View/download PDF

6. Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms:ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up5

Author

Hadoux, J., Lamarca, A., Grande, E., Deandreis, D., Kaltsas, G., Janson, E. T., Tombal, B., Pavel, M., Thariat, J., van Velthuysen, M. F., Herman, P., Dromain, C., Baudin, E., Berruti, A., Hadoux, J., Lamarca, A., Grande, E., Deandreis, D., Kaltsas, G., Janson, E. T., Tombal, B., Pavel, M., Thariat, J., van Velthuysen, M. F., Herman, P., Dromain, C., Baudin, E., and Berruti, A.

Published
2024

7. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial

Author

Baudin, E., Goichot, B., Berruti, A., Hadoux, J., Moalla, S., Laboureau, S., Nölting, S., Fouchardière, C. de la, Kienitz, T., Deutschbein, T., Zovato, S., Amar, L., Haissaguerre, M., Timmers, H.J.L.M., Niccoli, P., Faggiano, A., Angokai, M., Lamartina, L., Luca, F., Cosentini, D., Hahner, S., Beuschlein, F., Attard, M., Texier, M., Fassnacht, M., Baudin, E., Goichot, B., Berruti, A., Hadoux, J., Moalla, S., Laboureau, S., Nölting, S., Fouchardière, C. de la, Kienitz, T., Deutschbein, T., Zovato, S., Amar, L., Haissaguerre, M., Timmers, H.J.L.M., Niccoli, P., Faggiano, A., Angokai, M., Lamartina, L., Luca, F., Cosentini, D., Hahner, S., Beuschlein, F., Attard, M., Texier, M., and Fassnacht, M.

Abstract

Contains fulltext : 304834.pdf (Publisher’s version ) (Closed access), BACKGROUND: No randomised controlled trial has ever been done in patients with metastatic phaeochromocytomas and paragangliomas. Preclinical and first clinical evidence suggested beneficial effects of sunitinib. We aimed to evaluate the safety and efficacy of sunitinib in patients with metastatic phaeochromocytomas and paragangliomas. METHODS: FIRSTMAPPP is a multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial done at 14 academic centres across four European countries. Eligible participants were adults (aged ≥18 years) with sporadic or inherited progressive metastatic phaeochromocytomas and paragangliomas. Patients were randomly assigned (1:1) to receive either oral sunitinib (37·5 mg per day) or placebo. Randomisation was stratified according to SDHB status (mutation present vs wild type) and number of previous systemic therapies (0 vs ≥1). Primary endpoint was the rate of progression-free survival at 12 months according to real-time central review (Response Evaluation Criteria in Solid Tumours version 1.1). On the basis of a two-step Simon model, we aimed for the accrual of 78 patients, assuming a 20% improvement of the 12-month progression-free survival rate from 20% to 40%, to conclude that sunitinib is effective. Crossover from the placebo group was allowed. This trial is registered with ClinicalTrials.gov, number NCT01371201, and is closed for enrolment. FINDINGS: From Dec 1, 2011, to Jan 31, 2019, a total of 78 patients with progressive metastatic phaeochromocytomas and paragangliomas were enrolled (39 patients per group). 25 (32%) of 78 patients had germline SDHx variants and 54 (69%) had used previous therapies. The primary endpoint was met, with a 12-month progression-free survival in 14 of 39 patients (36% [90% CI 23-50]) in the sunitinib group. In the placebo group, the 12-month progression-free survival in seven of 39 patients was 19% (90% CI 11-31), validating the hypotheses of our study design. The most frequent gra

Published
2024

9. Évaluation de la réponse sur la masse mésentérique de tumeurs neuroendocrines intestinales à la radiothérapie interne vectorisée par Lu-177-DOTATATE

Author

Mansour, L. Al, primary, De Mestier, L., additional, Haissaguerre, M., additional, Afchain, P., additional, Hadoux, J., additional, Lecomte, T., additional, Morland, D., additional, Cottereau, A.S., additional, De Rycke, O., additional, Tlili, G., additional, Tordo, J., additional, Janier, M., additional, Deville, A., additional, and Walter, T., additional

Published
2024
Full Text
View/download PDF

11. Efficacité de Osilodrostat dans une nouvelle série de patients avec syndrome de Cushing intense et sévère par sécrétion ectopique d’ACTH (SE-ACTH)

Author

Decoudier, B., primary, Illouz, F., additional, Mosbah, H., additional, Bruzeau, J., additional, Trupin, J., additional, Richa, C., additional, Laloi, M., additional, Allanic, Y., additional, Colakoglu, E., additional, Laroche, S., additional, Rodien, P., additional, Vieira-Pinto, O., additional, Salenave, S., additional, Chanson, P., additional, Kamenicky, P., additional, Hadoux, J., additional, Maione, L., additional, Baudin, E., additional, and Young, J., additional

Published
2023
Full Text
View/download PDF

13. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

Author

Hadoux, J., Elisei, R., Brose, M. S., Hoff, A. O., Robinson, B. G., Gao, M., Jarzab, B., Isaev, P., Kopeckova, K., Wadsley, J., Fohrer, D., Keam, B., Bardet, S., Sherman, E. J., Tahara, M., Hu, M. I., Singh, R., Lin, Y., Soldatenkova, V., and Wright, J.

Subjects
*MEDULLARY thyroid carcinoma, *CLINICAL trials, *PROGRESSION-free survival, *TERMINATION of treatment, *ADVERSE health care events
Abstract

BACKGROUND Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in advanced RET-mutant medullary thyroid cancer in a phase 1-2 trial, but its efficacy as compared with approved multikinase inhibitors is unclear. METHODS We conducted a phase 3, randomized trial comparing selpercatinib as first-line therapy with the physician's choice of cabozantinib or vandetanib (control group). Eligible patients had progressive disease documented within 14 months before enrollment. The primary end point in the protocol-specified interim efficacy analysis was progression-free survival, assessed by blinded independent central review. Crossover to selpercatinib was permitted among patients in the control group after disease progression. Treatment failure-free survival, assessed by blinded independent central review, was a secondary, alpha-controlled end point that was to be tested only if progression-free survival was significant. Among the other secondary end points were overall response and safety. RESULTS A total of 291 patients underwent randomization. At a median follow-up of 12 months, median progression-free survival as assessed by blinded independent central review was not reached in the selpercatinib group and was 16.8 months (95% confidence interval ICI], 12.2 to 25.1) in the control group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.16 to 0.48; P<0.001). Progression-free survival at 12 months was 86.8% (95°/0 CI, 79.8 to 91.6) in the selpercatinib group and 65.7% (95% CI, 51.9 to 76.4) in the control group. Median treatment failurefree survival as assessed by Minded independent central review was not reached in the selpercatinib group and was 13.9 months in the control group (hazard ratio for disease progression, discontinuation due to treatment-related adverse events, or death, 0.25; 95% CI, 0.15 to 0.42; P<0.001). Treatment failure-free survival at 12 months was 86.296 (95% CI, 79.1 to 91.0) in the selpercatinib group and 62.1% (95% CI, 48.9 to 72.8) in the control group. The overall response was 69.4°/o (95°/o CI, 62.4 to 75.8) in the selpercatinib group and 38.896 (95% CI, 29.1 to 49.2) in the control group. Adverse events led to a dose reduction in 38.9°6 of the patients in the selpercatinib group, as compared with 77.3% in the control group, and to treatment discontinuation in 4.7% and 26.8%, respectively. CONCLUSIONS Selpercatinib treatment resulted in superior progression-free survival and treatment failure-free survival as compared with cabozantinib or vandetanib in patients with RET-mutant medullary thyroid cancer. (Funded by Loxo Oncology, a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, NCT0421133Z) [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network

Author

Faron, M., Naman, A., Delahousse, J., Hescot, S., Hadoux, J., Castinetti, F., Drui, D., Renoult-Pierre, P., Libe, R., Lamartina, L., Leboulleux, S., Al-Ghuzlan, A., Lombès, M., Paci, A., and Baudin, E.

Abstract

Purpose: Mitotane is the only approved treatment for metastatic adrenocortical carcinoma (ACC). Monitoring plasma levels is recommended, but its predictive value is insufficient. Methods: This prospective study of the French ENDOCAN-COMETE network aimed to investigate the prognostic role of plasma mitotane levels pharmacokinetics and free or bound to lipoprotein fraction measurements during six consecutive months. Lipoprotein fractions were isolated by ultracentrifugation, and mitotane level was determined by HPLC–UV. Total, free, and lipoprotein fraction bound plasma mitotane were monitored every two months for six months with morphological assessment. The primary endpoint was overall survival (OS). Results: 21 patients with metastatic ACC were included. Median overall survival was 23 months. The median free mitotane level per patient was 12% (± 7%), and the majority (88%) was bound to lipoprotein fractions. Several pharmacokinetics measures of total mitotane were related to OS: first level at one month (p= 0.026), mean level (p= 0.055), and area under the curve (AUC) (p= 0.048), with higher exposure associated to longer OS. Free mitotane (not bounded) and mitotane bounded to lipoprotein subfraction added no prognostic values. The relationship between the mitotane level and OS suggested a minimum “effective” threshold of 10–15 mg/L or an area under the curve above 100 mg/L/month with no individualized maximum value. Conclusion: This prospective study did not identify any added prognostic value of free mitotane level over the total level. Early total mitotane level measurements (before 3–6 months) were related to OS with a higher and faster exposure related to more prolonged survival.

Published
2024
Full Text
View/download PDF

15. Facteurs pronostiques des carcinomes anaplasiques de la thyroïde durant la dernière décennie au sein du réseau ENDOCAN-TUTHYREF

Author

Jannin, A., primary, Giudici, F., additional, De La Fouchardiere, C., additional, Al Ghuzlan, A., additional, Wassermann, J., additional, Chougnet, C.N., additional, Drui, D., additional, Godbert, Y., additional, Illouz, F., additional, Bardet, S., additional, Dygai-Cochet, I., additional, Roudaut, N., additional, Batisse-Lignier, M., additional, Groussin, L., additional, Klein, M., additional, Zerdoud, S., additional, Lamartina, L., additional, Baudin, E., additional, Decaussin-Petrucci, M., additional, Leteurtre, E., additional, Borson-Chazot, F., additional, Do Cao, C., additional, Borget, I., additional, and Hadoux, J., additional

Published
2022
Full Text
View/download PDF

16. BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network

Author

De La Fouchardiere, C., primary, Jannin, A., additional, Giudici, F., additional, Wassermann, J., additional, Chougnet, C.N., additional, Drui, D., additional, Godbert, Y., additional, Illouz, F., additional, Bardet, S., additional, Dygai-Cochet, I., additional, Roudaut, N., additional, Batisse-Lignier, M., additional, Groussin, L., additional, Klein, M., additional, Zerdoud, S., additional, Lamartina, L., additional, Baudin, E., additional, Borson-Chazot, F., additional, Do Cao, C., additional, Borget, I., additional, and Hadoux, J., additional

Published
2022
Full Text
View/download PDF

18. First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionuclide therapy with 177Lutetium – Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial, on behalf of the ENDOCAN RENATEN network and GTE

Author

Baudin, E., primary, Walter, T., additional, Docao, C., additional, Haissaguerre, M., additional, Hadoux, J., additional, Taieb, D., additional, Ansquer, C., additional, Dierickx, L., additional, De Mestier, L., additional, Deshayes, E., additional, Quak, E., additional, and Foulon, S., additional

Published
2022
Full Text
View/download PDF

19. Detection of myeloid malignancies through cfDNA profiling in patients with advanced stage cancer

Author

Tagliamento, M., primary, Aldea, M., additional, Verge, V., additional, Bayle, A., additional, Blanc-Durand, F., additional, Marinello, A., additional, Hadoux, J., additional, Loriot, Y., additional, Vasseur, D., additional, Nicotra, C., additional, Smolenschi, C., additional, Martin-Romano, P., additional, Hollebecque, A., additional, Ponce, S., additional, Lacroix, L., additional, Rouleau, E., additional, Marzac, C., additional, Italiano, A., additional, Besse, B., additional, and Micol, J.B., additional

Published
2022
Full Text
View/download PDF

21. 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial

Author

Baudin, E., primary, Walter, T.A., additional, Beron, A., additional, Smith, D., additional, Hadoux, J., additional, Lachachi, C., additional, Taieb, D., additional, Ansquer, C., additional, Dierickx, L.O., additional, de Mestier du Bourg, L., additional, Deshayes, E., additional, Quak, E., additional, Dahan, L., additional, Guimbaud, R., additional, Touchefeu, Y., additional, Haissaguerre, M., additional, Do Cao, C., additional, Lombard Bohas, C., additional, Attard, M., additional, and Foulon, S., additional

Published
2022
Full Text
View/download PDF

22. 1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)

Author

Hu, M.I., primary, Subbiah, V., additional, Mansfield, A.S., additional, Taylor, M., additional, Schuler, M.H.H., additional, Zhu, V., additional, Hadoux, J., additional, Curigliano, G., additional, Wirth, L.J., additional, Garralda, E., additional, Adkins, D.R., additional, Godbert, Y., additional, Ahn, M-J., additional, Cassier, P.A., additional, Cho, B.C., additional, Lin, C-C., additional, Barata, T., additional, Zalutskaya, A., additional, Scalori, A., additional, and Brose, M.S., additional

Published
2022
Full Text
View/download PDF

23. 1652P Molecular and pathological patterns of treatment failure in patients treated by RET selective inhibitors for metastatic medullary thyroid carcinoma

Author

Hadoux, J., primary, Al Ghuzlan, A., additional, Lamartina, L., additional, Attard, M., additional, Scoazec, J-Y., additional, Hartl, D.M., additional, Aldea, M., additional, Friboulet, L., additional, Italiano, A., additional, Besse, B., additional, Lacroix, L., additional, and Baudin, E., additional

Published
2022
Full Text
View/download PDF

24. 2MO EO2401 (EO) therapeutic vaccine for patients (pts) with adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP): Phase I/II SPENCER study

Author

Baudin, E., primary, Grisanti, S., additional, Fassnacht, M., additional, Menke-van der Houven van Oordt, C.W., additional, Haak, H., additional, de la Fouchardiere, C., additional, Subbiah, V., additional, Jimenez, C., additional, Capdevila Castillon, J., additional, Granberg, D., additional, Daugaard, K.G., additional, Kroiss, M., additional, Cosentini, D., additional, Kimpel, O., additional, Lamartina, L., additional, Hadoux, J., additional, Paillarse, J-M., additional, Chêne, L., additional, Fagerberg, J., additional, and Berruti, A., additional

Published
2022
Full Text
View/download PDF

26. 1647MO BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real-life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network

Author

de la Fouchardiere, C., primary, Jannin, A., additional, Giudici, F., additional, Wassermann, J., additional, Chougnet, C., additional, Drui, D., additional, Godbert, Y., additional, Illouz, F., additional, Bardet, S., additional, Roudaut, N., additional, Batisse Lignier, M., additional, Groussin, L., additional, Klein, M., additional, Zerdoud, S., additional, Lamartina, L., additional, Baudin, E., additional, Borson-Chazot, F., additional, Do Cao, C., additional, Borget, I., additional, and Hadoux, J., additional

Published
2022
Full Text
View/download PDF

33. Hypercortisolisme endogène et pneumocystose : une étude rétrospective multicentrique

Author

Lugat, A., primary, Lasolle, H., additional, François, M., additional, Benhenda, N., additional, Bricaire, L., additional, Cornu, E., additional, Cristante, J., additional, Hadoux, J., additional, Kerlan, V., additional, Le Bras, M., additional, Puerto, M., additional, Raverot, G., additional, Storey-London, C., additional, Drui, D., additional, and Haissaguerre, M., additional

Published
2021
Full Text
View/download PDF

34. Caractérisation des patients progressifs pendant la lutathérapie

Author

Molina, O., primary, Hindié, E., additional, Tlili, G., additional, Terrebonne, E., additional, Smith, D., additional, Gaye, D., additional, Tabarin, A., additional, Hadoux, J., additional, Walter, T., additional, Deshayes, E., additional, Courbon, F., additional, Dierickx, L., additional, Duval, M., additional, Hentic, O., additional, Laboureau, S., additional, Lacombe, M., additional, Jannin, A., additional, Do Cao, C., additional, Hautefeuille, V., additional, Taïeb, D., additional, Thuillier, P., additional, and Haissaguerre, M., additional

Published
2021
Full Text
View/download PDF

35. Essai randomisé en double aveugle du Sunitinib dans les phéochromocytomes et paragangliomes malins (PPGM) : résultats de l’étude internationale FIRSTMAPPP

Author

Baudin, E., primary, Goichot, B., additional, Berruti, A., additional, Hadoux, J., additional, Moalla, S., additional, Laboureau, S., additional, Noelting, S., additional, De La Fouchardière, C., additional, Kienitz, T., additional, Deutschbein, T., additional, Zovato, S., additional, Amar, L., additional, Tabarin, A., additional, Timmers, H., additional, Niccoli, P., additional, and Attard, M., additional

Published
2021
Full Text
View/download PDF

37. Pronosthyc: Prognostic factors in radioiodine refractory differentiated thyroid cancer with distant metastases, a multicentric study from the French ENDOCAN-TUTHYREF Network

Author

Sagnella, A., Lasolle, H., Godbert, Y., Do Cao, C., Drui, D., Hescot, S., Laramas, M., Sage, C., Wassermann, J., Roudaut, N., Illouz, F., Borson-Chazot, F., Abdelouahab, M.B., Hadoux, J., Borget, I., Buffet, C., and Lamartina, L.

Abstract

Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients with distant metastases have a heterogeneous prognosis, spanning from indolent to rapidly progressing disease. Our aim is to assess overall survival (OS) in RAI-R DTC patients and to identify the associated prognostic factors.

Published
2024
Full Text
View/download PDF

38. Évaluation des patients avec carcinome médullaire thyroïdien en réponse prolongée au vandetanib dans le réseau français ENDOCAN – TUTHYREF

Author

Lasolle, H., Lamartina, L., Do Cao, C., Buffet, C., Schneegans, O., Gauduchon, T., Drui, D., Benisvy, D., Grunenwald, S., Godbert, Y., Bardet, S., Batisse-Lignier, M., Chougnet, C., Nascimento, C., Roudaut, N., Illouz, F., Sajous, C., Hadoux, J., Borget, I., and Borson-Chazot, F.

Abstract

Le vandetanib est indiqué en première ligne (L1) dans les carcinomes médullaires thyroïdiens (CMT) requérant un traitement systémique. Dans la littérature, la durée médiane de traitement est d’environ 20 mois, un quart des patients peuvent présenter une réponse prolongée.

Published
2024
Full Text
View/download PDF

41. 567O First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): An academic double-blind trial investigating sunitinib

Author

Baudin, E., primary, Goichot, B., additional, Berruti, A., additional, Hadoux, J., additional, Moalla, S., additional, Laboureau, S., additional, Noelting, S., additional, de la Fouchardière, C., additional, Kienitz, T., additional, Deutschbein, T., additional, Zovato, S., additional, Amar, L., additional, Tabarin, A., additional, Timmers, H.J., additional, Niccoli, P., additional, Faggiano, A., additional, Beuschlein, F., additional, Attard, M., additional, Texier, M., additional, and Fassnacht, M., additional

Published
2021
Full Text
View/download PDF

43. LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network

Author

Walter, T., Lecomte, T., Hadoux, J., Niccoli, P., Saban-Roche, L., Gaye, E., Guimbaud, R., Baconnier, M., Hautefeuille, V., Do Cao, C., Petorin, C., Hentic Dhome, O., Perrier, M., Aparicio, T., Scoazec, J-Y., Lombard Bohas, C., Bin, S., Hervieu, V., Barritault, M., and Gerard, L.

Published
2023
Full Text
View/download PDF

47. L’évaluation d’un large panel de facteurs pronostiques/prédictifs potentiels dans le corticosurrénalome métastatique identifie P53 comme facteur pronostique indépendant

Author

Hescot, S., primary, Faron, M., additional, Kordahi, M., additional, Do Cao, C., additional, Hadoux, J., additional, Lamartina, L., additional, Naman, A., additional, Leboulleux, S., additional, Scoazec, J.Y., additional, Al Ghuzlan, A., additional, and Baudin, E., additional

Published
2020
Full Text
View/download PDF

49. 607P Prognostic value of early total, free and bound to lipoprotein fractions plasma mitotane measurements in advanced adrenocortical carcinoma at the time of mitotane initiation: A prospective study of the ENDOCAN-COMETE-cancer network

Author

Naman, A., primary, Delahousse, J., additional, Hescot, S., additional, Castinetti, F., additional, Hadoux, J., additional, Drui, D., additional, Renoult pierre, P., additional, Libe, R., additional, Lamartina, L., additional, Lombès, M., additional, Leboulleux, S., additional, Paci, A., additional, Faron, M., additional, and Baudin, E., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results